Co-Authors
This is a "connection" page, showing publications co-authored by YI-QIAN NANCY YOU and JOHN M SKIBBER.
Connection Strength
1.651
-
Multimodality salvage of recurrent disease after local excision for rectal cancer. Dis Colon Rectum. 2012 Dec; 55(12):1213-9.
Score: 0.454
-
Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer. Ann Surg Oncol. 2011 Apr; 18(4):989-96.
Score: 0.396
-
A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Netw. 2015 Jul; 13(7):865-72.
Score: 0.136
-
Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015 May; 150(5):402-9.
Score: 0.134
-
Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015 Mar 01; 150(3):245-51.
Score: 0.033
-
Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015 Jan; 150(1):17-22.
Score: 0.033
-
Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol. 2014 Sep 20; 32(27):2967-74.
Score: 0.032
-
Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience. J Surg Oncol. 2014 Jun; 109(7):652-8.
Score: 0.031
-
Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014 Apr 15; 120(8):1162-70.
Score: 0.031
-
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
Score: 0.030
-
Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer. Ann Surg Oncol. 2014 Feb; 21(2):507-12.
Score: 0.030
-
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
Score: 0.030
-
Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.
Score: 0.030
-
A novel risk-adjusted nomogram for rectal cancer surgery outcomes. JAMA Surg. 2013 Aug; 148(8):769-77.
Score: 0.030
-
An individualized conditional survival calculator for patients with rectal cancer. Dis Colon Rectum. 2013 May; 56(5):551-9.
Score: 0.029
-
Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2013 Feb; 56(2):135-41.
Score: 0.029
-
Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013 Feb; 20(2):482-90.
Score: 0.028
-
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20; 30(15):1770-6.
Score: 0.027
-
Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012 Sep; 19(9):2814-21.
Score: 0.027
-
Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation. Dis Colon Rectum. 2012 Apr; 55(4):371-7.
Score: 0.027
-
MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics. 2012 Mar-Apr; 32(2):389-409.
Score: 0.027
-
Reverse-hybrid robotic mesorectal excision for rectal cancer. Dis Colon Rectum. 2012 Feb; 55(2):228-33.
Score: 0.027